
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova's revenue for 2024 is projected to grow significantly, with management guiding sales expectations between $940 million and $955 million, building on a previous growth of 29% to $803 million. Additionally, the company is forecasting positive scenarios for its aura6000 product, anticipating potential market share increases leading to sales of $120 million in 2027 and $280 million by 2029. This strong sales outlook, combined with a focus on specialized cardiopulmonary and neuromodulation devices, supports a favorable financial trajectory for LivaNova.
Bears say
LivaNova's stock outlook is negatively impacted by anticipated revenue growth slowing to the low-single digits, primarily due to ongoing challenges in its Neuromodulation and Cardiovascular segments. Additionally, the company faces operational margin contraction and is projected to deliver earnings that fall below consensus expectations. Key risks further complicate LivaNova's situation, including the potential failure to secure FDA approval for its aura6000 device and slower-than-expected growth in its core Neuromodulation and Cardiopulmonary businesses.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares